PTGX Earnings & Financial Statements
Protagonist Therapeutics, Inc.
$136.28
-$2.21(-1.60%)
56
Overall
20
Value
90
Tech
60
Quality
Market Cap
$8.82B
Volume
679.04K
52W Range
$73.08 - $160.81
Target Price
$173.00
PTGX earnings and financial statements: Protagonist Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
PTGX Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $46.02M | $434.43M | $60.00M | $26.58M | $27.36M |
| Operating income | -$158.13M | $252.84M | -$93.65M | -$131.37M | -$125.84M |
| EBITDA | -$128.03M | $280.23M | -$75.64M | -$124.02M | -$123.07M |
| Net income | -$130.15M | $275.19M | -$78.95M | -$127.39M | -$125.55M |
| EPS (diluted) | $-2.05 | $4.23 | $-1.39 | $-2.60 | $-2.71 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $668.19M | $744.73M | $357.95M | $247.93M | $347.69M |
| Total liabilities | $53.48M | $69.43M | $21.27M | $32.32M | $47.67M |
| Shareholders’ equity | $614.71M | $675.29M | $336.68M | $215.61M | $300.02M |
| Cash and equivalents | $128.39M | $97.25M | $186.73M | $125.74M | $123.67M |
| Long-term debt | $8.04M | $10.36M | - | $1.14M | $3.66M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $57.67M | $184.15M | -$70.24M | -$108.14M | -$107.86M |
| Capital expenditure | -$1.59M | -$1.35M | -$609.0K | -$795.0K | -$1.10M |
| Free cash flow | $56.08M | $182.80M | -$70.84M | -$108.93M | -$108.97M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PTGX | $136.28 | -1.6% | 679.04K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Protagonist Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW